KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Income: 2010-2025

Historic Net Income for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Net Income rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2817.96%. This contributed to the annual value of $17.5 million for FY2024, which is 169.61% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Net Income is $27.9 million, which was down 53.20% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Net Income ranged from a high of $59.6 million in Q2 2025 and a low of -$27.4 million during Q1 2022.
  • Over the past 3 years, Rigel Pharmaceuticals' median Net Income value was $737,000 (recorded in 2023), while the average stood at $8.3 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 169.53% in 2022, then soared by 5,887.67% in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Net Income stood at -$22.6 million in 2021, then spiked by 106.20% to $1.4 million in 2022, then plummeted by 47.39% to $737,000 in 2023, then surged by 1,843.28% to $14.3 million in 2024, then surged by 124.62% to $27.9 million in 2025.
  • Its Net Income was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.